FY2025 EPS Estimate for BridgeBio Pharma Boosted by Analyst

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Cantor Fitzgerald raised their FY2025 earnings estimates for shares of BridgeBio Pharma in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($3.93) per share for the year, up from their prior estimate of ($4.62). Cantor Fitzgerald currently has a “Overweight” rating and a $95.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.12. The business had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. The firm’s quarterly revenue was down 44.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.20) earnings per share.

BBIO has been the topic of a number of other research reports. Scotiabank raised their price objective on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Citigroup lifted their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. UBS Group boosted their price target on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright raised their price objective on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. Finally, Redburn Atlantic began coverage on BridgeBio Pharma in a report on Monday, March 31st. They issued a “buy” rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.09.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $38.57 on Friday. The stock’s 50-day simple moving average is $34.06 and its 200-day simple moving average is $30.85. The firm has a market capitalization of $7.32 billion, a PE ratio of -13.53 and a beta of 1.08. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.54.

Insiders Place Their Bets

In other BridgeBio Pharma news, Director Andrea Ellis sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the transaction, the director now owns 12,000 shares in the company, valued at approximately $408,600. The trade was a 71.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares of the company’s stock, valued at approximately $634,841,604.16. This trade represents a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,309,191 shares of company stock valued at $208,544,821. 24.66% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BBIO. Vanguard Group Inc. boosted its position in shares of BridgeBio Pharma by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after purchasing an additional 879,059 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in BridgeBio Pharma by 1.9% during the fourth quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock worth $134,672,000 after buying an additional 89,521 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in BridgeBio Pharma by 140.1% during the fourth quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after buying an additional 2,448,000 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in BridgeBio Pharma by 1.1% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after buying an additional 40,000 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after buying an additional 912,439 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.